GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Small and Large Bowel/The IntAct Trial: ICG Fluorescence Angiography in Rectal Cancer Surgery

The IntAct Trial: ICG Fluorescence Angiography in Rectal Cancer Surgery

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated August 1, 2025

Quick Answer

The IntAct trial investigated the use of indocyanine green (ICG) fluorescence angiography as a tool to reduce anastomotic leaks during rectal cancer surgery. Anastomotic leaks, which occur when the surgical connection between two sections of the bowel fails, are a significant complication in rectal cancer surgery, leading to increased morbidity, prolonged hospital stays, and higher healthcare costs.


The IntAct trial investigated the use of indocyanine green (ICG) fluorescence angiography as a tool to reduce anastomotic leaks during rectal cancer surgery. Anastomotic leaks, which occur when the surgical connection between two sections of the bowel fails, are a significant complication in rectal cancer surgery, leading to increased morbidity, prolonged hospital stays, and higher healthcare costs.

### Key Findings of the IntAct Trial:

1. **Primary Outcome:**

  • The trial aimed to determine whether ICG fluorescence angiography could significantly reduce clinical anastomotic leaks. However, the reduction in clinical leaks was not statistically significant.

2. **Overall Leak Reduction:**

  • Despite the primary outcome not reaching statistical significance, the use of ICG fluorescence angiography was associated with a reduction in the overall number of anastomotic leaks, particularly in less severe grades (grades A and B).

3. **Intraoperative Adjustments:**

  • Surgeons using ICG fluorescence angiography made more intraoperative adjustments to improve the perfusion of the anastomosis. This suggests that the technique provided valuable real-time feedback on blood flow, allowing surgeons to optimize the surgical connection.

4. **Postoperative Outcomes:**

  • Postoperative outcomes, including quality of life and mortality, were similar between the ICG group and the control group. This indicates that while ICG may help reduce certain complications, it did not significantly impact broader postoperative recovery metrics.

5. **Cost-Effectiveness:**

  • The trial found modest cost savings associated with ICG use, suggesting that the technique could be cost-effective. By potentially avoiding some anastomotic leaks, hospitals may reduce the need for additional interventions and extended hospital stays.

6. **Severe Leaks:**

  • The study noted that severe leaks (grade C) are likely influenced by factors beyond perfusion, such as patient comorbidities, surgical technique, or underlying disease biology. As a result, ICG fluorescence angiography may be less effective in preventing these more severe complications.

### Implications of the IntAct Trial:

The IntAct trial highlights the potential benefits of ICG fluorescence angiography in rectal cancer surgery, particularly in reducing less severe anastomotic leaks and providing intraoperative guidance for surgeons. However, its impact on clinical leak rates overall and severe leaks was limited. The technique may still be a valuable tool in the surgical armamentarium, especially given its potential cost-effectiveness and ability to improve perfusion during surgery.

Future research may focus on refining the use of ICG, identifying patient populations that would benefit most, and addressing factors contributing to severe leaks.

Related Q&A

Anal High-Grade Squamous Intraepithelial Lesions (HSIL): BJS | March 2026

Introduction: Anal squamous cell carcinoma is an increasingly common but largely preventable cancer. Most cases arise from persistent high-risk human papillomavirus (HPV) infection, progressing through high-grade squamous intraepithelial lesions (HSIL). This comprehensive review summarizes the...

Post-Infection DGBI (PI-DGBI): Gut | July 2026

Introduction: Acute infectious gastroenteritis can trigger persistent gastrointestinal symptoms long after the infection has resolved, leading to post-infection disorders of gut-brain interaction (PI-DGBI). This global Rome Foundation study evaluated the prevalence, risk factors, and clinical...

FMT in IBS: Gastroenterology | July 2026

Introduction: Gut microbiota alterations have been implicated in the pathogenesis of irritable bowel syndrome (IBS), making fecal microbiota transplantation (FMT) a promising therapeutic strategy. However, clinical trials have reported conflicting results. This updated meta-analysis evaluated...

Laparoscopic vs Open Adhesiolysis for Bowel Obstruction: JAMA Surgery | June 2026

Introduction: Laparoscopic adhesiolysis offers several short-term advantages over open surgery for adhesive small bowel obstruction (ASBO). However, its long-term impact on recurrence, quality of life, and incisional hernia remains uncertain. The LASSO trial provides the...

DPP-4 Inhibition Targets the Gut–Brain Axis in Parkinson's Disease: Gut | July 2026

Introduction: Growing evidence suggests that Parkinson's disease (PD) may originate in the gut, with pathological α-synuclein spreading to the brain through the vagus nerve. This study investigated whether sitagliptin, a widely used DPP-4 inhibitor for...

Bedside Ultrasound Outperforms Abdominal X-Ray in Neonatal Necrotizing Enterocolitis: Frontiers in Pediatrics | July 2026

Introduction: Necrotizing enterocolitis (NEC) is one of the most serious gastrointestinal emergencies in neonates. Early identification of infants requiring surgical intervention is critical but remains challenging. This study compared bedside abdominal ultrasonography (US) with abdominal...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer